A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: A California cancer consortium trial

Journal of Thoracic Oncology

Volumn 7, Issue 3, 2012, Pages 574-578

  Gitlitz, Barbara J ^a   Tsao Wei, Denice D ^a   Groshen, Susan ^a   Davies, Angela ^b   Koczywas, Marianna ^c   Belani, Chandra P ^d   Argiris, Athanassios ^e   Ramalingam, Suresh ^f   Vokes, Everett E ^g   Edelman, Martin ^h   Hoffman, Philip ^g   Ballas, Marc S ⁱ   Liu, Stephen V ^a   Gandara, David R ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d PENN STATE CANCER INSTITUTE   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f EMORY UNIVERSITY   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

ⁱ NEW YORK UNIVERSITY   (United States)

Author keywords

Eribulin mesylate; Halichondrin B; Non small cell lung cancer; Taxane refractory; Taxane sensitive

Indexed keywords

ERIBULIN; HALICHONDRIN B; PLATINUM; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CONSTIPATION; COUGHING; DISEASE DURATION; DIZZINESS; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; SODIUM BLOOD LEVEL; THROMBOCYTOPENIA; TREATMENT DURATION; UNITED STATES;

EID: 84857918226     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31823f43ca     Document Type: Article

References (14)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med 2002;346:92-98. (Pubitemid 34438899)
3. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103. (Pubitemid 30324363)
4. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597. (Pubitemid 41079796)
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med 2005; 353:123-132. (Pubitemid 41058344)
6. Bissery MC, Nohynek G, Sanderink GJ, et al. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 1995;6:339-368.
7. Schimming R, Mason KA, Hunter N, et al. Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother Pharmacol 1999;43:165-172. (Pubitemid 29045036)
8. Uemura D, Takahashi K, Yamamoto T, et al. Norhalichondrin A: an antitumor polyether macrolide from a marine sponge. J Am Chem Soc 1985;107:4796-4798. (Pubitemid 16244006)
9. Kuznetsov G, TenDyke K, Yu MJ, et al. Anti-proliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxelresistant human cancer cells in vitro. Proc Am Assoc Cancer Res 2007;48:275 (abstr C58).
10. Twelves C, Loesch D, Blum JL, et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. ASCO 2010 Annual Meeting. J Clin Oncol 2010;28(18 Suppl):abstr CRA1004.
11. Synold TW, Morgan RJ, Newman EM, et al. A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer Consortium trial. J Clin Oncol 2005;23(16 Suppl): abstr 3036.
12. Tan AR, Ruin EH, Walton DC, et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009;15:4213-4219.
13. Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010;28:3922-3928.
14. Spira AI, Iannotti NO, Savin MA, et al. Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(18 Suppl):abstr 7546.